AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01165307 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NovaSure® Radiofrequency Endometrial Ablation
Description: Radiofrequency endometrial ablation is performed in the outpatient surgery department. Subjects receive intravenous medication, determined by the attending anesthesiologist, sufficient to induce conscious sedation during the procedure.
Study NCT02920190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: 1.8 mg Liraglutide administered subcutaneously once daily for 12 consecutive months
Study NCT02280434 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CBP-307
Study NCT02280434 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02163395 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: FullCeram implant
Description: FullCeram implantation
Study NCT01965327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon Gamma-1b
Description: Subjects will begin by taking 10 mcg/m2 of IFN-g-1b for the first two weeks of the study. Dose will be escalated to 25 mcg/m2 of IFN-g-1b for weeks three and four of the study. Finally, the dose will be escalated to 50 mcg/m2 of IFN-g-1b for the last eight weeks of the study, which is the current dose approved by the FDA for children.~All doses will be administered via subcutaneous injection.
Study NCT00005793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Study NCT00005793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Study NCT00005793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Study NCT00005793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Study NCT03466905 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ambulant assessment
Study NCT04654845 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulpotomy
Description: Access to pulp chamber. Removal of the pulp chamber tissue. Use of Sodium Hypochlorite (5.25% NaCl) during the whole procedure and in the amount considered appropriate by each operator.~Wait until confirmation of absence of bleeding from the conducts. Placement of polytetrafluroethylene in pulp chamber. Placement of temporary filling. Reduction of the occlusal surface of the tooth until there is no contact with the articulating paper from 200μ.
Study NCT04654845 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulpectomy
Description: Access to pulp chamber. Removal of the pulp chamber tissue. Use of Sodium Hypochlorite (5.25% NaCl) during the whole procedure and in the amount considered appropriate by each operator.~Establishment of working length by means of Electronic Apex Locator and a number 8 K file.~Access to all conducts with a number 10 K file. Rotary instrumentation with one reciprocating system up to working length and up to an apical diameter of 25.~Placement of polytetrafluroethylene in pulp chamber. No intermediate medication will be filled into the conducts.~Placement of temporary filling. Reduction of the occlusal surface of the tooth until there is no contact with the articulating paper from 200μ.
Study NCT00120211 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Accelerated Radiotherapy Fractionation
Description: Radiation Therapy 6 fractions per week
Study NCT00120211 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Accelerated Radiotherapy Fractionation
Description: Radiotherapy 5 fractions per week
Study NCT02755818 — intervention group
Intervention type: DRUG
Intervention: Heparin
Description: This is not an interventional study. The investigators use heparin at 50unit/kg of body weight to release enzyme lipoprotein lipase (LPL) from the body. LPL level will be used as part of calculation of lipid analysis and measurements
Study NCT03778268 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sentinel lymph node biopsy
Description: 1. Injecting carbon nanoparticles (CNP)\[Not Equipped with near-infrared fluorescent vascular imager\] or CNP combining Indocyanine Green(ICG)\[Equipped with near-infrared fluorescent vascular imager\].~2. Identifying and removing sentinel lymph nodes.~3. Staining all nodes using hematoxylin-eosin staining.
Study NCT02782312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICS+LABA
Description: Seretide is inhaled for one year
Study NCT02782312 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: routine therapy
Description: routine therapy for one year
Study NCT02904070 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vaginal swabbing
Study NCT04344080 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CytoSorb-Therapy
Description: Additional use of Cytosorb-Adsorber in patients with COVID-19 and need for extracorporeal circulation (continuous renal replacement therapy or extracorporeal membrane oxygenation)
Study NCT02604888 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: MEXIS/M6S Patent - lotion against alopecia
Description: For greatest problems 20 drops on the scalp per day for 6 months. For minor problems 10 drops on the scalp three times per week for 6 months.
Study NCT01908192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NaBen®
Description: The Study Treatment is NaBen®, which will look, and will be packaged and maintained exactly the same way as the Control Treatment (Placebo).
Study NCT01908192 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The ingredients in the Control Treatment are exactly the same as in the Study Treatment, except without the primary active ingredient.
Study NCT00929110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrronium bromide
Description: Glycopyrronium bromide was supplied in powder-filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
Study NCT00929110 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to glycopyrronium bromide
Description: Placebo to glycopyrronium bromide was supplied in powder-filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
Study NCT00929110 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium
Description: Tiotropium was supplied in powder-filled capsules together with the Handihaler® device.
Study NCT04197739 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amikacin
Description: Patients in the intervention arm will receive a fixed, single daily dose of amikacin, 500 mg, a day.~Patients in the Comparator arm will receive a weight adjusted loading dose of amikacin (15 mg/kg adjusted body weight) and continue in adjusted intervals according to the Barnes Jewish Hospital nomogram
Study NCT04197739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amikacin
Description: Patients in the intervention arm will receive a fixed, single daily dose of amikacin, 500 mg, a day.~Patients in the Comparator arm will receive a weight adjusted loading dose of amikacin (15 mg/kg adjusted body weight) and continue in adjusted intervals according to the Barnes Jewish Hospital nomogram
Study NCT00004242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Study NCT00004242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Study NCT00004242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Study NCT04606108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab in Combination With Neoadjuvant Chemotherapy
Description: camrelizumab in combination with Liposome doxorubicin and Ifosfamide
Study NCT03720951 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: pudendal nerve
Description: Fluoroscopic-guided pulsed R.F. to pudendal nerve bilaterally under image guidance
Study NCT03720951 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: sacral n roots
Description: Fluoroscopic-guided pulsed R.F. to nerve roots S 2, 3, 4 bilaterally under image guidance
Study NCT02048423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: IV Ketamine, 0.5 mg/kg X 15 mins. in PACU
Study NCT02334163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitazoxanide
Description: 500 mg nitazoxanide tablets twice daily
Study NCT02334163 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral lactulose
Description: Oral lactulose (65%)
Study NCT02334163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral lactulose
Description: Oral lactulose (65%)
Study NCT02334163 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: 250 mg metronidazole tablets every 8 hours
Study NCT02334163 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifaximine
Description: Two 200 mg rifaximine tablets every 8 hours
Study NCT00933595 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smoking Cessation
Description: A Motivational Interview session (\~40-50 minutes) will be delivered by a trained nurse coordinator.~Treatment with varenicline (1 mg daily during week 1 (pre-quit week) followed by 1 mg twice daily for weeks 2-12)or nicotine replacement therapy (21 mg of a skin patch + nicotine gum 4 mg ad lib added for breakthrough craving up to 20 pieces/day.
Study NCT02130869 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD133+ selected autologous stem cell infusion
Description: Hematopoietic stem cells will be collected from children with high-risk solid tumors. After collection, they will be immuno-magnetically selected using CD133 as a marker in efforts to reduce tumor cell contamination in the stem cell graft. After high dose chemotherapy, those selected stem cells will be infused, followed shortly thereafter by an infusion of haploidentical natural killer cells.
Study NCT02130869 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL-2
Description: Following infusion of haploidentical natural killer cells, interleukin-2 (IL-2) subcutaneously (SQ) will be given to support the in vivo survival of donor NK cells.
Study NCT02130869 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hu14.18K322A
Description: Participants with neuroblastoma (Group A) will receive hu14.18K322A intravenously (IV).
Study NCT02130869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Given IV - Group A only.
Study NCT02130869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV - All groups.
Study NCT02130869 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: Given SQ - All groups.
Study NCT02130869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Given IV - Group B only.
Study NCT02130869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV - Group B and Group C. In case of etoposide reactions, etoposide phosphate will be given.
Study NCT02130869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV - Group B only.
Study NCT02130869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV - Group C only.
Study NCT03449251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apelin
Description: Apelin is an endogenous peptide that activate a single G-protein couple receptor. Apelin inhibits insulin secretion, decreases glucose levels and increases insulin sensitivity.
Study NCT02130869 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Haploidentical natural killer cell infusion
Description: NK cell product will be collected from donors using leukapheresis procedures. The autologous hematopoietic stem cell graft product will be positively selected using the investigational CliniMACS device and CD133 Microbead reagent. Following standard laboratory procedures, the NK cell product will be enumerated and assessed for viable cell content. NK cells will be infused by slow IV push over 3 to 15 minutes immediately after processing, evaluation and release testing.
Study NCT02130869 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: Given SQ - All Groups.
Study NCT02130869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide phosphate
Description: In case of etoposide reactions, etoposide phosphate will be given IV. - Group B and Group C only.
Study NCT02130869 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMACS
Description: The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
Study NCT03186313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dactavira Plus
Description: 1 Single daily dose (2 Tablets) of Dactavira Plus each tablet contains (EPGCG 200 mg , Sofosbuvir 200mg, Daclatasvir 30 mg, Ribavirin 400 mg) for 12 weeks.
Study NCT03186313 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sofosbuvir + Daclatasvir + Ribavirin
Description: Daily dose including Sofosbuvir 400 mg , Daclatasvir 60 mg \& Ribavirin 800 mg for 12 weeks.
Study NCT03186313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dactavira
Description: Single daily dose (1 Tablet) of Dactavira each tablet contains (EPGCG 400 mg , Sofosbuvir 400mg, Daclatasvir 60 mg) for 12 weeks
Study NCT03186313 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sofosbuvir + Daclatasvir
Description: Daily dose Sofosbuvir 400 mg \& Daclatasvir 60 mg for 12 weeks
Study NCT00435071 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Carpal Tunnel Release Surgery
Description: Patient will have large incision size during carpal tunnel release surgery.
Study NCT00435071 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Carpal tunnel release surgery
Description: Patient will have a small incision size during carpal tunnel release surgery.
Study NCT01855958 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DIMST
Description: The investigators used electro acupuncture of 2 Hz during 30 minutes.
Study NCT01855958 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Placebo-sham
Description: Electro acupuncture with rubber electrodes, without current passing.
Study NCT04686916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IP2018
Description: Test drug
Study NCT04686916 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02507570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: used concomitantly
Study NCT02507570 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radium ra 223 dichloride
Study NCT03150082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GR37547 tablet
Description: A single tablet of GR37547 should be taken orally with 240 mL of water. GR37547 500 mg tablet will be a white to off white capsule shape with break line on upper side and embossed GSK500on lower side.
Study NCT03150082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin reference tablet
Description: A single tablet of ciprofloxacin reference should be taken orally with 240 mL of water. Ciprofloxacin 500 mg reference will be nearly white to slightly yellowish film coated oblong tablets with break line and ''CIP 500 marked on upper side and BAYER on lower side.
Study NCT03208816 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: symptom management program for chemotherapy patients
Description: Nurses will call study participants two times a week, to proactively assess and manage symptoms they might be experiencing during chemotherapy.
Study NCT04224246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gamma Hydroxybutyrate
Description: Gamma-OH® will be administered intravenously at a dose of 20 mg/kg/h for 6 hours
Study NCT02941315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etiologic treatment,anti-myocardial remodeling
Description: When the etiology was diagnosed clearly by cardiac magnetic resonance(CMR), participants were treated with drugs including etiologic treatment,anti-myocardial remodeling according to guidelines for treatment of cardiomyopathy.
Study NCT02941315 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: anti-myocardial remodeling
Description: When the etiology was not diagnosed clearly by cardiac magnetic resonance(CMR), in participant without companioned with acute heart failure, participants were treated with drugs including anti-myocardial remodeling according to guidelines for treatment of cardiomyopathy.
Study NCT02941315 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: anti-myocardial remodeling,anti-acute heart failure
Description: When the etiology was not diagnosed clearly by cardiac magnetic resonance(CMR), in participant companioned with acute heart failure, participants were treated with drugs including anti-myocardial remodeling and anti- acute failure according to guidelines.
Study NCT02941315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etiological, anti-remodeling and symptom treatment
Description: When the etiology was diagnosed clearly by cardiac magnetic resonance(CMR), in participants were companioned with acute heart failure, the participant should be treated with drugs including etiologic treatment,anti-myocardial remodeling and anti-acute heart failure according to guidelines for treatment of cardiomyopathy.
Study NCT03294642 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Potatoes
Description: Pureed russet potatoes will be used as a carbohydrate supplement for participants during one of the three cycling challenges.
Study NCT03294642 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carbohydrate Gel
Description: Commercially available PowerBar PowerGel will be used for the carbohydrate gel condition during one of the three cycling challenges.
Study NCT03294642 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Water
Description: Water will be used as a control during one of the three cycling challenges (participants will not receive any carbohydrate supplementation).
Study NCT04512963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progerinin
Description: 100 mg/g nano-suspension for oral use
Study NCT04512963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: A substance that has no therapeutic effect, used as a control in testing Progerinin
Study NCT03496389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Gabapentin 300mg daily
Study NCT03496389 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: Tramadol 50mg QID
Study NCT03496389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panadol
Description: Panadol 500mg QID
Study NCT03496389 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Panadol
Description: Panadol 500mg QID
Study NCT04339049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine spray
Description: four puffs (10 mg/puff) of lidocaine spray before tenaculum placement plus vaginal placebo 3 hours before IUD insertion
Study NCT04339049 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vaginal misoprostol
Description: vaginal misoprostol 200 mcg given 3 hours before IUD insertion plus four puffs of saline spray before tenaculum placement
Study NCT04339049 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: vaginal placebo given 3 hours before IUD insertion plus four puffs of saline spray before tenaculum placement
Study NCT01944657 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Supplemental TMS
Description: Supplemental TMS treatments will be administered utilizing the NeuroStar TMS Therapy® Machine. Treatment will be fixed at 120% of magnetic field intensity relative to the subject's resting motor threshold at a repetition rate of ten magnetic pulses per second, with a stimulus train duration (i.e., on time) of 4 seconds and an inter train interval (i.e., off time) of 26 seconds. The left dorsolateral prefrontal cortex will be the treatment location and this site will be determined by adjusting the TMS coil 5 cm anterior to the motor threshold location along a left superior oblique plane with a rotation point at about the tip of the patient's nose. Each treatment session will last approximately 37.5 minutes administering 3,000 magnetic pulses over the course of the treatment session.
Study NCT01944657 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medication Monotherapy
Description: These medications could include bupropion (Wellbutrin and others), citalopram (Celexa and others), Clomipramine (Ananfranil and others), duloxetine (Cymbalta), escitalopram (Lexapro and others), fluoxetine (Prozac and others), fluvoxamine (Luvox and others), imipramine (Tofranil and others), mirtazapine (Remeron and others), nortriptylatine (Pamelor, Aventyl, and others), paroxetine (Paxil, Pexeva, and others), phenelzine (Nardil), sertraline (Zoloft and others), tranylcypromine (Parnate and others), venlafaxine (Effexor and others).
Study NCT03658291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sanjin tablets
Description: Sanjin tablets,3 pills /time, 4 times/ day, for 7 days+levofloxacin simulants,0.1g, po bid, for 7 days.